Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Novo’s Wegovy Nears Japan Approval as First MASH Therapy
Quick Look: An MHLW panel backed Wegovy as Japan’s first treatment for MASH, recommending its use in non-cirrhotic disease with moderate or advanced liver fibrosis. The session also supported three NMEs — Biogen’s diroximel fumarate, Santen’s netarsudil, and Sanofi’s rilzabrutinib…
To read the full story
Related Article
- Wegovy’s MASH Label Expansion and More Up for Japan Panel Review on May 29
May 18, 2026
- Sanofi Files ITP Drug Rilzabrutinib in Japan
October 6, 2025
- Chugai Seeks Avastin Label Expansion for Neurofibromatosis Type 2
September 25, 2025
- Novo Japan Files Sogroya for SGA-Related and Noonan Syndrome Short Stature
July 31, 2025
- Santen Files Glaucoma Drug Rhopressa in Japan
July 31, 2025
REGULATORY
- MHLW Lifts Part of Approval Conditions for Takeda’s Vyvanse
June 9, 2026
- Drug Makers Seek Govt Support for Immunoglobulin Plant Investments: LDP Hearing
June 9, 2026
- Japan Govt Likely to Slim Down Honebuto, but Details Remain Elusive
June 8, 2026
- Leqembi, Kisunla Labels Revised to Strengthen ARIA Monitoring
June 8, 2026
- Japan Tightens Oversight of Mounjaro Resales: Health Minister
June 8, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…